GlassScriptPhysician profile
Ivan Carreras
NPI 1528298312
$4,822.09
in general payments reported to CMS, 2019-2025
22 companies · $488 in 2025
The $488 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,102 · 2020: $718 · 2021: $916 · 2022: $185 · 2023: $177 · 2024: $1,236 · 2025: $488.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,901.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,900.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,066.19 | 2023-2025 | Otezla, Repatha, Repatha |
| Novo Nordisk INC | $878.53 | 2019-2025 | Rybelsus, Ozempic |
| Sanofi-Aventis U.S. LLC | $511.98 | 2019-2022 | |
| Lilly USA, LLC | $508.09 | 2019-2025 | Zepbound, Mounjaro |
| Esperion Therapeutics, INC. | $417.00 | 2021 | |
| Pfizer INC. | $251.45 | 2019-2021 | |
| Dexcom, INC. | $216.48 | 2021-2023 | Dexcom G6 Transmitter |
| Corcept Therapeutics | $214.56 | 2023-2025 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $171.29 | 2020-2024 | Jardiance |
| Merck Sharp & Dohme LLC | $145.45 | 2019-2023 | Steglatro |
| Novartis Pharmaceuticals Corporation | $120.36 | 2019 | |
| Exact Sciences Corporation | $107.05 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Abbott Laboratories | $48.98 | 2022-2024 | Freestyle Libre 3 |
| Abbvie INC. | $41.76 | 2021 | |
| Inspire Medical Systems, INC. | $37.86 | 2024 | Inspire |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insightec,INC | $22.26 | 2025 | Exablate |
| Glaxosmithkline, LLC. | $21.53 | 2022 | |
| Amarin Pharma, INC. | $21.20 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $20.07 | 2024 | Farxiga |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ivan Carreras listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.